Physician profile
William Sullivan
NPI 1033177894
$8,433.47
in general payments reported to CMS, 2019-2025
24 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $594 · 2021: $1,069 · 2022: $1,426 · 2023: $1,465 · 2024: $1,761 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,357 · Education: $76.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,356.66 |
| Education | $76.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,139.95 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,816.44 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,606.78 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $471.05 | 2019-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $379.51 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $321.67 | 2019-2025 | |
| Genzyme Corporation | $302.90 | 2019-2021 | |
| Alk-Abello, INC | $161.41 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $158.79 | 2021-2022 | |
| Kaleo, INC. | $141.61 | 2020-2022 | |
| Grifols USA, LLC | $126.39 | 2021-2025 | Xembify |
| Octapharma USA, INC. | $122.29 | 2023-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $101.71 | 2020-2022 | |
| Incyte Corporation | $99.36 | 2022 | |
| Abbvie INC. | $98.35 | 2022-2023 | Rinvoq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.09 | 2020-2023 | Cyltezo |
| Amgen INC. | $67.19 | 2022-2024 | Tezspire |
| Pfizer INC. | $55.55 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $41.91 | 2021 | |
| Leo Pharma INC. | $35.65 | 2023 | Adbry |
| Uswm, LLC | $28.00 | 2021 | |
| Biocryst US Sales Co., LLC | $27.75 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $24.41 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $23.71 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.